Novartis has entered into a definitive merger agreement to acquire Genoptix, Inc. Novartis will commence an all cash tender offer for all outstanding shares of common stock of Genoptix at $25 per share, giving the transaction an equity value of approximately $470 million and an enterprise value of $330 million. The cash offer price represents a premium of 27% premium over Genoptix’ closing price from January 21, 2011. The transaction is expected to close within the first half of 2011. ...